Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
-Klein MW, Grujovic A, Obradovic M, Hoffmann M, Lu X, Kirsch S, Treitschke S, Koestler C, Weidele K, Irlbeck C, Botteron C, Werno C, Polzer B, Guzvic M, Buchholz S, Ruemmele P, Heine N, Rose-John S, Klein CA (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: AMER ASSOC CANCER RESEARCH
City/Town: PHILADELPHIA
Conference Proceedings Title: CANCER RESEARCH
Event location: Atlanta, GA
DOI: 10.1158/1538-7445.AM2019-LB-312
Involved external institutions
Universität Regensburg
Germany (DE)
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin (ITEM) / Fraunhofer Institute for Toxicology and Experimental Medicine
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Christian-Albrechts-Universität zu Kiel
Germany (DE)
Germany (DE)
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin (ITEM) / Fraunhofer Institute for Toxicology and Experimental Medicine
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Christian-Albrechts-Universität zu Kiel
Germany (DE)
How to cite
APA:
-Klein, M.W., Grujovic, A., Obradovic, M., Hoffmann, M., Lu, X., Kirsch, S.,... Klein, C.A. (2019). Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency. In CANCER RESEARCH. Atlanta, GA, US: PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MLA:
-Klein, Melanie Werner, et al. "Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency." Proceedings of the AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta, GA PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2019.
BibTeX: Download